Drugs / Quadrivalent influenza virus split vaccine (MDCK cells)
Quadrivalent influenza virus split vaccine (MDCK cells)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06342349 | Mar → Dec 2024 | influenza | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent influenza virus split vaccine (MDCK cells) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06342349 ↗ |
| Modality | Vaccine | “Quadrivalent influenza vaccine made from cell matrix (0.5ml/dose).” NCT06342349 ↗ |